Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.
Int J Hematol
; 114(5): 626-629, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1310613
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA (mRNA) vaccine is unique. We report a case of a 69-year-old male with multiple comorbidities who presented to the hospital with severe fatigue and shortness of breath. Labs were significant for thrombocytopenia, anemia, and hemolysis with schistocytes consistent with TTP with a second dose of BNT162b2 mRNA vaccine as a likely culprit been documented.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purpura, Thrombotic Thrombocytopenic
/
Immunization, Secondary
/
Pandemics
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
Type of study:
Case report
/
Observational study
Topics:
Long Covid
/
Vaccines
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Int J Hematol
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
S12185-021-03190-y
Similar
MEDLINE
...
LILACS
LIS